LOBE:CC News and Press, Lobe Sciences Ltd. From 02/23/24

A look at the top 10 most actives in Canada BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 13.5% to $3.72 on volume of 15,947,557 shares Coelacanth Energy Inc. (CEI) fell 1.3% to $0.74 on volume of 12,564,158 shares Consolidated Lithium Metals Inc. (CLM) rose 33.3% to $0.02 on vo...

A look at the top 10 most actives in Canada CI First Asset Energy Giants Covered Call ETF (NXF) rose 0.0% to $5.95 on volume of 2,727,114 shares AlphaGen Intelligence Corp. (AIC) fell 25.0% to $0.045 on volume of 2,693,705 shares Harvest Healthcare Leaders Income ETF (HHL) rose 0.0% to $8...

12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"...

Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformat...

L-130 passes 12 months ongoing stability Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a propriet...

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Officer,...

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase agreeme...

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an Inte...

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogue All subjects dosed with no significant adverse events to date Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative m...

Phillips also named President of Altemia & Co., a Lobe Sciences Company Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxte...